Medical oncologists conclude their discussion with a review of the toxicity profiles of treatments for diffuse large B-cell lymphoma.
Carla Casulo, MD
Advertisement
Articles by Carla Casulo, MD
Carla Casulo, MD, and the Oncology Brothers review the treatment algorithm for patients with relapsed/refractory DLBCL.
The Oncology Brothers and Carla Casulo, MD, discuss treatment practices for patients with stage III or IV diffuse large B-cell lymphoma.
A hematologist-oncologist joins the Oncology Brothers do discuss first-line treatment practices for patients with stage I or II diffuse large B-cell lymphoma.
Carla Casulo, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to provide clinical insights on biopsy practices and discuss the importance of cell of origin in treating diffuse large B-cell lymphoma (DLBCL).
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
2
CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer
3
Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population
4
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
5
